NCT06824519View on ClinicalTrials.gov

Clinical Trials of Quadrivalent Influenza Vaccine

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

620

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2026

Conditions
Influenza, Human
Interventions
BIOLOGICAL

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (low dose)

Inject 1 dose of low-dose vaccine

BIOLOGICAL

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant placebo (low dose)

Inject 1 dose of low-dose placebo

BIOLOGICAL

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (high dose)

Inject 1 dose of high-dose vaccine

BIOLOGICAL

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant placebo (high dose)

Inject 1 dose of high-dose placebo

BIOLOGICAL

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Inject 1 dose of positive control vaccine

Trial Locations (1)

Unknown

RECRUITING

Hebei Province Centers for Disease Control and Prevention, Shijiazhuang

All Listed Sponsors
lead

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY